[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600152":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":7,"responsibleParty":12,"collaborators":7,"id":16,"slug":7,"hasResults":17,"nctId":18,"briefTitle":19,"officialTitle":20,"acronym":7,"eligibilityCriteria":21,"healthyVolunteers":17,"sex":22,"minAge":23,"maxAge":7,"enrollmentInfo":24,"targetDuration":7,"studyType":27,"phases":7,"briefSummary":28,"conditions":29,"keywords":7,"overallStatus":32,"whyStopped":7,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":7},{"fullName":5,"class":6},"Gangnam Severance Hospital","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Tumor grade (I or II vs. III)","We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score",{"type":13,"investigatorFullName":14,"investigatorTitle":15,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Sung Gwe Ahn","Professor","100600152",false,"NCT07093775","Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score","Prognostic Implication of Tumor Grade in Patients With Node-negative Breast Cancer Aged ≤ 50 Years With 21-gene Recurrence Scores of 11-25","Inclusion Criteria:\n\n* Patients with hormone receptor-positive, HER2-negative early-stage breast cancer\n* Patients treated between January 2011 and December 2023\n* Patients with available clinicopathologic data and 21-gene Oncotype DX assay results confirmed through electronic medical records\n\nExclusion Criteria:\n\n* Patients with breast cancer under the age of 20\n* Patients diagnosed with stage IV breast cancer\n* Patients for whom clinicopathologic data cannot be retrieved from electronic medical records","ALL","20 Years",{"count":25,"type":26},4000,"ESTIMATED","OBSERVATIONAL","To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.",[30,31],"Breast Cancer","Tumor Grade","NOT_YET_RECRUITING","2025-07-22",{"date":35,"type":36},"2025-07-30","ACTUAL",{"date":38,"type":26},"2025-07",{"date":40,"type":26},"2026-03",{"name":5,"class":6}]